The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
NCT ID: NCT05360615
Last Updated: 2025-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
147 participants
INTERVENTIONAL
2022-07-01
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
NCT06030843
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
NCT05614115
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
NCT06483074
Empagliflozin in Heart Failure Dialysis Patients
NCT05967156
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
NCT03591991
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Empagliflozin
Empagliflozin 10 MG
SGLT2 inhibitors
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Empagliflozin 10 MG
SGLT2 inhibitors
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CrCl \> 20
Exclusion Criteria
* post kidney transplant
* previous use of SGLT2 Inhibitors
* history of ketoacidosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nattachai Srisawat ,M.D.
Assistant Professor.Nattachai Srisawat
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nattachai Srisawat
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Chest Institute of Thailand
Nonthaburi, Mueang Nonthaburi District, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB.211/65
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.